Member Info for Kiwi_

FDA approval due on Stonechecker, recent sales and business development broker/partner, very tight freefloat and often fill or kill to buy. Well worth grabbing a few imho.

Artificial Intelligence used in the diagnosis and accurate mapping of brain tumours and kidney stones

IQAI had some large buys yesterday and started to head North again I see

Hello Wassatt

Could it be an intraday RNS or is it Monday?

Here is the link

https://www.investegate.co.uk/iq-ai-limited--iqai-/rns/publication-of-annual-report/201904301200185788X/

Let me just highlight a couple of points from that:

1/In the first quarter of 2019 the Company completed its first sale of StoneChecker in the United Kingdom to the National Health Service.

2/The Company's products are now sold in the USA, UK, The Netherlands, Switzerland, Germany, Greece and South Korea (including South East Asia). Our objectives for 2019 are to expand sales and continue to develop new products which utilise areas of our expertise where we believe we have scientific and technological leadership. As a result of product development and new users, sales have continued to accelerate in 2019.

3/IB has recently expanded its development team with software engineers experienced in artificial intelligence ("AI"). The Company intends to strategically incorporate AI to further enhance and automate its fractional tumour burden ("FTB") mapping for brain tumour treatment monitoring. IB's FTB maps distinguishes viable brain tumour from treatment associated changes. Currently, FTB map generation involves the manual identification of contrast enhancing regions of interest (ROI). While this step is greatly simplified using IB's Delta T1 maps, it does require knowledge of brain anatomy and may take in excess of 15 minutes to complete, depending on the invasiveness of the tumour. Leveraging AI to automate this step will provide clinicians with a fully-automated process of generating a biologically-based quantitative imaging biomarker, and a validated measure of tumour burden, on a per-voxel basis. In addition, the Company will leverage AI to enhance current intermediate steps including automated brain masking and segmentation capabilities.

Yeah, I think it justifies far more than a £5 million market cap. But that is just my opinion. ;)

RNS Number : 5788X
IQ-AI Limited
30 April 2019
IQ-AI Ltd
("IQ-AI" or the "Company")
Publication of Annual Report

During 2018, the Company sold or trialled software at many of the United States' most well-regarded hospitals and specialist clinics. IB Neuro remains the only 'biopsy confirmed' neuro perfusion software available on the market. Publicising this to all potential users is a key element of the Company's 2019 plans. We also intend to explore collaborative business relationships where our sales reach can be expanded by encouraging other companies' sales teams to promote our product for financial reward. This work is already underway with a series of resellers such as aycan Medical Systems, QMENTA, Blackford and Medimsight.

Subsequent to the year end, the Company sold an instance of the IB Neuro product suite to Dr Marion Smits of Erasmus University, Rotterdam. Dr Smits, one of the world's leading researchers in the field of neuroradiology, is Professor of Applied Physiological Imaging and Neuroradiologist at Erasmus MC, Vice President of the European Society for Magnetic Resonance in Medicine and Biology, and Chair of Neuroradiology of the Radiological Society of The Netherlands.

Dr Smits stated, "We appreciate IB Neuro's ability to accurately create quantitative perfusion maps for detecting regions of aggressive tumour and for longitudinal assessment of treatment response which will ultimately influence how we diagnose, track and treat brain tumour patients." Dr Smits added, "It is critical to know if a change in an imaging biomarker accurately represents a tumour's biological background and whether changes in the tumour's appearance are due to tumour growth or response to treatment. Without it, surgeons, radiotherapists and oncologists may require more tests or require more time to follow-up on the patients and to know, with confidence, that a treatment protocol is effective."

Dr Smits' comments echo those made by other leaders in the field of neuroradiology.
The Company sold and installed its first StoneChecker software in South Korea through its distributor, demonstrating that the remote sale and servicing of the product is a viable business model. The Company will make international expansion a key objective for 2019.

In the first quarter of 2019 the Company completed its first sale of StoneChecker in the United Kingdom to the National Health Service.

As you can see Wilfred less than a handful of RNSs but a shed load of gleaming information, moreover highlighting what else is in the tool box of IQAI that is not Stonchecker. To be fair I am just as excited about the brain imaging abilities as I am with Stonechecker

28 November 2018

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics® Update



Appointment of a South Korean Distributor

Imaging Biometrics, LLC ("IB") has appointed Korea Motion ISG ("Korea Motion") as its first distributor in South East Asia. Korean Motion will sell IB's full range of diagnostic imaging products in the areas of brain tumor detection using perfusion maps and the monitoring of brain tumor development. These products have been presented to several leading South Korean hospitals over the last few months, generating significant potential sales interest.

David Smith, CEO of Imaging Biometrics commented, "Our South Korean partner recently demonstrated their enthusiasm and competence in the medical software field through the introduction of StoneChecker securing the first commercial order for that product earlier this month. After trialing the full Imaging Biometrics range with several hospitals in recent months we are confident they will repeat this success with our products for detecting and monitoring brain tumors. This latest agreement marks the start of a concerted effort by management to develop global markets for Imaging Biometrics' products, building upon the success we are achieving in the United States."

ISO 13485:2016 Certification

Imaging Biometrics has received ISO 13485:2016 certification for Medical Device and Quality Management Systems. This ISO certification is required for regulatory purposes specific to the medical device industry.

ISO13485:2016 is an internationally recognised quality standard supporting the design, development, manufacture, and distribution of medical devices. To be certified, companies must demonstrate their ability to provide medical devices and services that consistently fulfill customer and regulatory requirements.

IB offers quantitative and highly-accurate solutions for a variety of neurological and other disorders. Over the years, IB has worked closely with leading scientists and clinicians to overcome limitations that affect conventional imaging. Now customisable and streamlined solutions can be seamlessly integrated in any sized healthcare system.

"This certification underscores our company's steadfast commitment of providing high-quality products to our clients," said IB's CEO, David Smith. "Maintaining a world-class quality management system is a key goal of IB, and our clients can feel confident that our quality management system provides a solid framework for how we conduct business,".

https://www.investegate.co.uk/iq-ai-limited--iqai-/rns/imaging-biometrics--update/201811280700026455I/

Here is the link, but first re-read the following words yourself from that RNS:

"Without IB Rad Tech, we would not be able to process the high volume of studies we see at our site," said Dr. John Karis, MD, Director of MRI and brain imaging for the Department of Neuroradiology at Barrow Neurological Institute, Dignity Health St. Joseph's Hospital and Medical Center. "Our MR Technologists are now able to quickly and consistently generate IB's advanced maps, and the clinicians trust the science on which Delta T1 and FTBs are based", added Josef Debbins, PhD, Staff Scientist, Keller Center for Imaging Innovation at Barrow.

David Smith, CEO of IB, said, "Using this automated normalisation algorithm within an IB Rad Tech workflow enables objective longitudinal assessment and can help assess whether a certain treatment protocol is working for brain tumor patients. Removing the variability of the manually-placed ROI is a more repeatable and faster method to do inter- and intra-study comparisons for multi-center clinical trials as well."

https://www.investegate.co.uk/iq-ai-limited--iqai-/rns/installation-at-barrow-neurological-institute/201812110700099988J/

RNS Number : 9988J
IQ-AI Limited
11 December 2018


IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics® installation at Barrow Neurological Institute

Imaging Biometrics®, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), announced today that Barrow Neurological Institute: Dignity Health, St. Joseph's Hospital and Medical Center ("BNI") has installed a new IB Rad Tech software platform to help assess treatment response for patients with brain tumors. BNI has led the way in the development of cutting-edge diagnosis, treatment, and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world. IB Rad Tech was chosen for its ability to efficiently generate quantitative maps of enhancing regions of tumor (Delta T1) and fractional tumor burden ("FTB"). IB's perfusion-derived FTB maps have been shown to aid clinicians in distinguishing tumor from non-tumor tissue.

IB Rad Tech offers customised workflows that automate the generation of sophisticated maps, outputs quality assurance indices, and can allow manual acknowledgement and intervention during intermediate processing steps. For example, one workflow used in generating quantitative Delta T1 and FTB maps relies on an exclusive machine-learned calibration technology termed "standardisation", which works for all platforms and field strengths. This step has proven superior to conventional normalisation techniques as it eliminates the need for the manual placement of regions of interest (ROIs) by radiology staff or physicians thereby reducing error and improving workflow efficiencies.

David Smith, CEO of IB, said, "Using this automated normalisation algorithm within an IB Rad Tech workflow enables objective longitudinal assessment and can help assess whether a certain treatment protocol is working for brain tumor patients. Removing the variability of the manually-placed ROI is a more repeatable and faster method to do inter- and intra-study comparisons for multi-center clinical trials as well."

"Without IB Rad Tech, we would not be able to process the high volume of studies we see at our site," said Dr. John Karis, MD, Director of MRI and brain imaging for the Department of Neuroradiology at Barrow Neurological Institute, Dignity Health St. Joseph's Hospital and Medical Center. "Our MR Technologists are now able to quickly and consistently generate IB's advanced maps, and the clinicians trust the science on which Delta T1 and FTBs are based", added Josef Debbins, PhD, Staff Scientist, Keller Center for Imaging Innovation at Barrow.

Once again Wilfred notice how they are not discussing Stonechecker? There is far more going on here than Stonechecker

IQ-AI Limited
First Commercial Sale of StoneChecker Software
RNS Number : 5417H
IQ-AI Limited
16 November 2018


IQ-AI Limited

("IQ-AI" or the "Company")

First Commercial Sale of StoneChecker Software

IQ-AI is pleased to announce the first commercial sale of its StoneChecker Software.

The Company's South Korean distributor has received its first order for the product from a prominent South Korean hospital.

David Smith, Chief Operating Officer of IQ-AI commented, "We are delighted to announce this significant commercial milestone for StoneChecker Software. The enthusiasm and commercial interest with which the product has been greeted upon its introduction to South Korea bodes well for the global market. We look forward to making further announcements as we expand distribution."

Commercial sales NOT reliant on FDA approval since 16 November 2018

https://www.investegate.co.uk/iq-ai-limited--iqai-/rns/first-commercial-sale-of-stonechecker-software/201811160700035417H/

Wilfred RNS

2 April 2019



IQ-AI Ltd

("IQ-AI" or the "Company")



Imaging Biometrics Update





Michael Schmainda, President of Imaging Biometrics: "This is the first study that directly compares the single-dose (no preload), low flip angle method to the conventional double-dose method for creation of rCBV maps. This study is a significant step towards creating the standard in DSC MRI for brain tumor patients, and it has the added benefit of a reducing the amount of contrast agent required to obtain good quality output. This marks an important step towards our ultimate goal of providing a contrast free option for MR imaging."

STOP READING BULLETIN BOARDS AND START READING RNSs, here is the link just for you. Notice the lack of discussuin regarding Stonechecker in this one, as you should NOW clearly be able to see there is far more to IQAI than just Stonechecker

https://www.investegate.co.uk/iq-ai-limited--iqai-/rns/imaging-biometrics-update/201904020700227423U/

Wilfred, you really need to do some research here as the opportunity is lost on you. We are not reliant on FDA, we have a full suite of other products anyway. These products are licenced to sell across the globe. CorTech would not have signed up with us if this was not the case

FDA is USA only, not UK or any other country for that matter of which Stonechecker is already approved

IQAI is MED's little AI brother, super small market cap with low shares in issue and similar pharmacutical deals on the cards such as IQAI £5 Million MC, 34% of shares in free float. Director skin in the game = 29%, recently signed a business development and sales agreement with CorTech labs

That is insane, can sell higher than that already

Restrictions on large amounts to Buy again

300K Buy just gone through